“ Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience ”, Clinics, vol. 70, no. 8, pp. 550–555, Aug. 2015, doi: 10.6061/clinics/2015(08)04.